128 related articles for article (PubMed ID: 37992586)
21. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.
Ponseti JM; Gamez J; Azem J; López-Cano M; Vilallonga R; Armengol M
Ann N Y Acad Sci; 2008; 1132():254-63. PubMed ID: 18096852
[TBL] [Abstract][Full Text] [Related]
22. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
23. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
[TBL] [Abstract][Full Text] [Related]
24. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review.
Sriwastava S; Tandon M; Kataria S; Daimee M; Sultan S
J Neurol; 2021 Aug; 268(8):2690-2696. PubMed ID: 33047223
[TBL] [Abstract][Full Text] [Related]
25. Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
Stascheit F; Grittner U; Hoffmann S; Mergenthaler P; Schroeter M; Ruck T; Pawlitzki M; Blaes F; Kaiser J; Schara U; Della-Marina A; Thieme A; Hagenacker T; Jacobi C; Berger B; Urban PP; Knop KC; Schalke B; Lee DH; Kalischewski P; Wiendl H; Meisel A
J Neurol; 2023 Jan; 270(1):1-12. PubMed ID: 36166068
[TBL] [Abstract][Full Text] [Related]
26. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
27. Case Report: tacrolimus toxicity in the setting of concurrent Paxlovid use in a heart-transplant recipient.
Modi S; Kahwash R; Kissling K
Eur Heart J Case Rep; 2023 May; 7(5):ytad193. PubMed ID: 37252201
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
29. [Meningitis caused by Listeria monocytogenes in a patient with myasthenia gravis being treated with tacrolimus].
Rodríguez D; Cid-Rodríguez MC; Núñez-Alvarez ML; González-Vázquez E; Lustres-Pérez M
Rev Neurol; 2005 Mar 16-31; 40(6):383. PubMed ID: 15795876
[No Abstract] [Full Text] [Related]
30. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
31. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment with prednisolone and tacrolimus for myasthenia gravis with invasive thymoma.
Miura S; Azuma K; Yamada K; Takamori S; Kawahara A; Noda K; Ayabe M; Kage M; Aizawa H; Taniwaki T
Acta Neurol Belg; 2010 Mar; 110(1):107-9. PubMed ID: 20514937
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
Itani K; Nakamura M; Wate R; Kaneko S; Fujita K; Iida S; Morise S; Murakami A; Kunieda T; Takenouchi N; Yakushiji Y; Kusaka H
Neuromuscul Disord; 2021 Jun; 31(6):512-518. PubMed ID: 33903022
[TBL] [Abstract][Full Text] [Related]
34. Spontaneously resolving late-onset ocular myasthenia related to COVID-19. A case report.
Popescu C
Acta Myol; 2023; 42(2-3):89-91. PubMed ID: 38090545
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of myasthenia gravis with tacrolimus.
Evoli A; Di Schino C; Marsili F; Punzi C
Muscle Nerve; 2002 Jan; 25(1):111-4. PubMed ID: 11754194
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
Konishi T; Yoshiyama Y; Takamori M; Saida T
J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
[TBL] [Abstract][Full Text] [Related]
37. Effect of Paxlovid on Tacrolimus Concentration in Perioperative Kidney Transplant Patients Infected With COVID-19: A Case Report.
Liu Y; Liu Y; Cai C; Hui F; Zhang Y; Wang B; Wang X; Zhang Y; Song X; He L; Yang H
Transplant Proc; 2023 Oct; 55(8):1822-1825. PubMed ID: 37558545
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous and sustained remission of intractable myasthenia gravis and focal segmental glomerulosclerosis with tacrolimus treatment.
Chung S; Park CW; Song J; Kim JA; Shin SJ; Chang YS
Clin Nephrol; 2008 Jul; 70(1):59-61. PubMed ID: 18793550
[TBL] [Abstract][Full Text] [Related]
39. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
Yoshikawa H; Kiuchi T; Saida T; Takamori M
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):970-7. PubMed ID: 21784757
[TBL] [Abstract][Full Text] [Related]
40. The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis.
Galassi G
Neurol Sci; 2022 Oct; 43(10):5803-5804. PubMed ID: 35759066
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
